We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Taiwan's Bureau of National Health Insurance (NHI) has announced that it will no longer reimburse a number of medicines that it considers are over-prescribed.
Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) today announced that the underwriters have exercised in full their over-allotment option to purchase 750,000 shares of common stock at the public offering price of $12.40 per share.
InNexus Biotechnology, Inc. (the "Company") has negotiated a private placement with U.S. institutional sources led by SDS Capital Group SPC, Ltd. as a principle investor.
Introgen Therapeutics Inc. says China issued a patent to the University of Texas for various genetic combination therapies used with the p53 gene and conventional chemotherapy or radiation.
Indian drug maker Lupin Ltd. said on Monday it had entered into an agreement with Japan's Kyowa Pharmaceutical Industry Company Ltd. to market drugs in Japan.
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today announced the results of operations for its second quarter and the six-month period ended June 30, 2005.